drug_name event_name drug_id event_id drug_and_event_name
4 Morphine Cataract 1110410 375545 Morphine & Cataract 
## Chronograph ##

## Basic demographic table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 327 100 Total 1000 100 Total 1000 100 Total 1000 100
Sex gender = FEMALE 185 57 Sex gender = FEMALE 613 61 Sex gender = FEMALE 560 56 Sex gender = FEMALE 546 55
gender = MALE 142 43 gender = MALE 387 39 gender = MALE 440 44 gender = MALE 454 45
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 3 1 (20,30] 5 0 (20,30] 6 1 (20,30] 9 1
(30,40] 9 3 (30,40] 28 3 (30,40] 18 2 (30,40] 11 1
(40,50] 7 2 (40,50] 54 5 (40,50] 34 3 (40,50] 42 4
(50,60] 19 6 (50,60] 64 6 (50,60] 57 6 (50,60] 57 6
(60,70] 88 27 (60,70] 204 20 (60,70] 223 22 (60,70] 230 23
(70,80] 109 33 (70,80] 369 37 (70,80] 361 36 (70,80] 386 39
(80,90] 73 22 (80,90] 228 23 (80,90] 228 23 (80,90] 222 22
(90,110] 19 6 (90,110] 48 5 (90,110] 73 7 (90,110] 43 4
Median 74 IQR=(68, 81) Median 74 IQR=(68, 82) Median 75 IQR=(68, 82) Median 74 IQR=(68, 81) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 327) % (n = 1,000) Std.Diff Characteristic % (n = 327) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 0.6 2.2 0.14
25 - 29 0.9 0.4 -0.06 Visual system disorder 50.8 31.7 -0.39
30 - 34 0.3 1.0 0.09 Medical history: Cardiovascular disease
35 - 39 1.8 1.3 -0.04 Atrial fibrillation 45.0 29.9 -0.31
40 - 44 0.9 2.3 0.11 Cerebrovascular disease 14.1 10.9 -0.10
45 - 49 1.2 2.9 0.12 Coronary arteriosclerosis 46.5 34.6 -0.24
50 - 54 1.5 3.2 0.11 Heart disease 80.4 63.6 -0.38
55 - 59 3.4 3.3 0.00 Heart failure 37.3 28.3 -0.19
60 - 64 5.5 3.4 -0.10 Ischemic heart disease 21.1 16.8 -0.11
65 - 69 15.9 14.3 -0.04 Peripheral vascular disease 42.8 32.2 -0.22
70 - 74 20.5 20.2 -0.01 Pulmonary embolism 6.1 3.1 -0.14
75 - 79 17.1 17.5 0.01 Venous thrombosis 9.8 8.2 -0.06
80 - 84 14.4 13.4 -0.03 Medical history: Neoplasms
85 - 89 9.2 10.4 0.04 Hematologic neoplasm 14.1 10.5 -0.11
90 - 94 4.6 3.9 -0.03 Malignant lymphoma 8.9 4.4 -0.18
95 - 99 2.1 2.0 -0.01 Malignant neoplasm of anorectum 1.2 0.8 -0.04
100 - 104 0.6 0.5 -0.02 Malignant neoplastic disease 42.5 31.3 -0.23
Gender: female 56.6 61.3 0.10 Malignant tumor of breast 6.7 5.4 -0.06
Medical history: General Malignant tumor of colon 7.6 3.4 -0.19
Acute respiratory disease 33.0 25.0 -0.18 Malignant tumor of lung 4.9 3.9 -0.05
Attention deficit hyperactivity disorder 0.9 0.5 -0.05 Malignant tumor of urinary bladder 6.4 3.6 -0.13
Chronic liver disease 3.4 3.6 0.01 Medication use
Chronic obstructive lung disease 17.1 11.4 -0.16 Agents acting on the renin-angiotensin system 59.0 64.7 0.12
Crohn’s disease 0.9 1.0 0.01 Antibacterials for systemic use 51.7 47.5 -0.08
Dementia 16.8 15.7 -0.03 Antidepressants 51.4 54.3 0.06
Depressive disorder 14.1 13.2 -0.03 Antiepileptics 30.6 33.6 0.06
Diabetes mellitus 71.9 57.9 -0.30 Antiinflammatory and antirheumatic products 36.4 37.0 0.01
Gastroesophageal reflux disease 20.5 18.1 -0.06 Antineoplastic agents 16.5 12.9 -0.10
Gastrointestinal hemorrhage 12.8 7.3 -0.18 Antipsoriatics 0 0.6 0.11
Human immunodeficiency virus infection 0.9 1.4 0.05 Antithrombotic agents 47.7 46.5 -0.02
Hyperlipidemia 38.2 28.9 -0.20 Beta blocking agents 54.1 56.4 0.05
Hypertensive disorder 7.0 4.6 -0.10 Calcium channel blockers 42.8 47.4 0.09
Lesion of liver 4.0 4.3 0.02 Diuretics 58.1 62.7 0.09
Obesity 9.5 6.7 -0.10 Drugs for acid related disorders 37.0 45.4 0.17
Osteoarthritis 55.0 46.2 -0.18 Drugs for obstructive airway diseases 33.9 34.5 0.01
Pneumonia 9.5 6.5 -0.11 Drugs used in diabetes 47.1 51.2 0.08
Psoriasis 1.8 2.2 0.03 Immunosuppressants 6.1 6.0 0.00
Renal impairment 35.8 28.9 -0.15 Lipid modifying agents 60.9 65.1 0.09
Rheumatoid arthritis 8.0 7.2 -0.03 Opioids 31.2 35.1 0.08
Schizophrenia 8.3 7.0 -0.05 Psycholeptics 52.6 54.1 0.03
Ulcerative colitis 0.6 0.7 0.01 Psychostimulants, agents used for adhd and nootropics 10.7 15.3 0.14
Urinary tract infectious disease 30.9 23.0 -0.18 
## Event vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.3 1.6 0.03
25 - 29 0.4 0.6 0.03 Visual system disorder 45.9 32.3 -0.28
30 - 34 0.5 0.8 0.04 Medical history: Cardiovascular disease
35 - 39 1.3 0.4 -0.10 Atrial fibrillation 36.8 28.2 -0.18
40 - 44 1.2 0.9 -0.03 Cerebrovascular disease 14.2 9.2 -0.16
45 - 49 2.1 3.0 0.06 Coronary arteriosclerosis 40.3 29.6 -0.23
50 - 54 2.0 2.7 0.05 Heart disease 73.9 57.7 -0.35
55 - 59 3.9 2.8 -0.06 Heart failure 33.4 23.9 -0.21
60 - 64 2.6 3.1 0.03 Ischemic heart disease 20.0 13.4 -0.18
65 - 69 16.3 15.6 -0.02 Peripheral vascular disease 38.5 27.9 -0.23
70 - 74 18.3 22.5 0.10 Pulmonary embolism 3.6 2.4 -0.07
75 - 79 18.9 18.1 -0.02 Venous thrombosis 10.4 8.8 -0.05
80 - 84 12.8 13.9 0.03 Medical history: Neoplasms
85 - 89 11.0 9.4 -0.05 Hematologic neoplasm 12.4 8.6 -0.12
90 - 94 4.9 3.9 -0.05 Malignant lymphoma 4.9 3.8 -0.05
95 - 99 3.1 2.0 -0.07 Malignant neoplasm of anorectum 2.5 2.1 -0.03
100 - 104 0.7 0.3 -0.06 Malignant neoplastic disease 36.1 28.5 -0.16
Gender: female 56.0 54.6 -0.03 Malignant tumor of breast 4.7 3.8 -0.04
Medical history: General Malignant tumor of colon 5.3 3.3 -0.10
Acute respiratory disease 26.2 20.4 -0.14 Malignant tumor of lung 4.0 4.6 0.03
Attention deficit hyperactivity disorder 0.5 0.1 -0.07 Malignant tumor of urinary bladder 4.3 3.0 -0.07
Chronic liver disease 3.2 3.6 0.02 Medication use
Chronic obstructive lung disease 11.1 8.4 -0.09 Agents acting on the renin-angiotensin system 41.1 0 -1.18
Crohn’s disease 0.8 0.7 -0.01 Antibacterials for systemic use 34.4 0 -1.02
Dementia 13.9 11.5 -0.07 Antidepressants 34.0 0 -1.02
Depressive disorder 9.8 7.1 -0.10 Antiepileptics 18.1 0 -0.66
Diabetes mellitus 64.2 48.8 -0.31 Antiinflammatory and antirheumatic products 20.3 0 -0.71
Gastroesophageal reflux disease 18.1 13.9 -0.11 Antineoplastic agents 12.0 0 -0.52
Gastrointestinal hemorrhage 8.5 5.8 -0.10 Antipsoriatics 0.5 0 -0.10
Human immunodeficiency virus infection 0.4 0.4 0.00 Antithrombotic agents 32.1 0 -0.97
Hyperlipidemia 34.4 24.0 -0.23 Beta blocking agents 36.3 0 -1.07
Hypertensive disorder 5.4 4.9 -0.02 Calcium channel blockers 29.7 0 -0.92
Lesion of liver 4.2 4.1 -0.01 Diuretics 43.5 0 -1.24
Obesity 8.0 5.6 -0.10 Drugs for acid related disorders 26.0 0 -0.84
Osteoarthritis 53.8 40.7 -0.26 Drugs for obstructive airway diseases 22.0 0 -0.75
Pneumonia 4.6 5.4 0.04 Drugs used in diabetes 29.4 0 -0.91
Psoriasis 2.3 1.7 -0.04 Immunosuppressants 4.5 0 -0.31
Renal impairment 27.6 22.1 -0.13 Lipid modifying agents 42.5 0 -1.22
Rheumatoid arthritis 7.5 7.0 -0.02 Opioids 20.3 0 -0.71
Schizophrenia 4.4 4.3 0.00 Psycholeptics 33.3 0 -1.00
Ulcerative colitis 0.3 0.2 -0.02 Psychostimulants, agents used for adhd and nootropics 8.6 0 -0.43
Urinary tract infectious disease 25.9 18.6 -0.18 
## Drug vs. All ##
Characteristic % (n = 1,000) % (n = 1,000) Std.Diff Characteristic % (n = 1,000) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 1.3 1.6 0.03
25 - 29 0.4 0.6 0.03 Visual system disorder 45.9 32.3 -0.28
30 - 34 0.5 0.8 0.04 Medical history: Cardiovascular disease
35 - 39 1.3 0.4 -0.10 Atrial fibrillation 36.8 28.2 -0.18
40 - 44 1.2 0.9 -0.03 Cerebrovascular disease 14.2 9.2 -0.16
45 - 49 2.1 3.0 0.06 Coronary arteriosclerosis 40.3 29.6 -0.23
50 - 54 2.0 2.7 0.05 Heart disease 73.9 57.7 -0.35
55 - 59 3.9 2.8 -0.06 Heart failure 33.4 23.9 -0.21
60 - 64 2.6 3.1 0.03 Ischemic heart disease 20.0 13.4 -0.18
65 - 69 16.3 15.6 -0.02 Peripheral vascular disease 38.5 27.9 -0.23
70 - 74 18.3 22.5 0.10 Pulmonary embolism 3.6 2.4 -0.07
75 - 79 18.9 18.1 -0.02 Venous thrombosis 10.4 8.8 -0.05
80 - 84 12.8 13.9 0.03 Medical history: Neoplasms
85 - 89 11.0 9.4 -0.05 Hematologic neoplasm 12.4 8.6 -0.12
90 - 94 4.9 3.9 -0.05 Malignant lymphoma 4.9 3.8 -0.05
95 - 99 3.1 2.0 -0.07 Malignant neoplasm of anorectum 2.5 2.1 -0.03
100 - 104 0.7 0.3 -0.06 Malignant neoplastic disease 36.1 28.5 -0.16
Gender: female 56.0 54.6 -0.03 Malignant tumor of breast 4.7 3.8 -0.04
Medical history: General Malignant tumor of colon 5.3 3.3 -0.10
Acute respiratory disease 26.2 20.4 -0.14 Malignant tumor of lung 4.0 4.6 0.03
Attention deficit hyperactivity disorder 0.5 0.1 -0.07 Malignant tumor of urinary bladder 4.3 3.0 -0.07
Chronic liver disease 3.2 3.6 0.02 Medication use
Chronic obstructive lung disease 11.1 8.4 -0.09 Agents acting on the renin-angiotensin system 41.1 0 -1.18
Crohn’s disease 0.8 0.7 -0.01 Antibacterials for systemic use 34.4 0 -1.02
Dementia 13.9 11.5 -0.07 Antidepressants 34.0 0 -1.02
Depressive disorder 9.8 7.1 -0.10 Antiepileptics 18.1 0 -0.66
Diabetes mellitus 64.2 48.8 -0.31 Antiinflammatory and antirheumatic products 20.3 0 -0.71
Gastroesophageal reflux disease 18.1 13.9 -0.11 Antineoplastic agents 12.0 0 -0.52
Gastrointestinal hemorrhage 8.5 5.8 -0.10 Antipsoriatics 0.5 0 -0.10
Human immunodeficiency virus infection 0.4 0.4 0.00 Antithrombotic agents 32.1 0 -0.97
Hyperlipidemia 34.4 24.0 -0.23 Beta blocking agents 36.3 0 -1.07
Hypertensive disorder 5.4 4.9 -0.02 Calcium channel blockers 29.7 0 -0.92
Lesion of liver 4.2 4.1 -0.01 Diuretics 43.5 0 -1.24
Obesity 8.0 5.6 -0.10 Drugs for acid related disorders 26.0 0 -0.84
Osteoarthritis 53.8 40.7 -0.26 Drugs for obstructive airway diseases 22.0 0 -0.75
Pneumonia 4.6 5.4 0.04 Drugs used in diabetes 29.4 0 -0.91
Psoriasis 2.3 1.7 -0.04 Immunosuppressants 4.5 0 -0.31
Renal impairment 27.6 22.1 -0.13 Lipid modifying agents 42.5 0 -1.22
Rheumatoid arthritis 7.5 7.0 -0.02 Opioids 20.3 0 -0.71
Schizophrenia 4.4 4.3 0.00 Psycholeptics 33.3 0 -1.00
Ulcerative colitis 0.3 0.2 -0.02 Psychostimulants, agents used for adhd and nootropics 8.6 0 -0.43
Urinary tract infectious disease 25.9 18.6 -0.18 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
beta blocking agents 354
antithrombotic agents 312
nervous system 277
cardiovascular system 266
alimentary tract and metabolism 263
respiratory system 226
blood and blood forming organs 211
antiepileptics 200
lipid modifying agents 199
lipid modifying agents, plain 199
sensory organs 199
all other therapeutic products 198
ophthalmologicals 198
analgesics 197
agents acting on the renin-angiotensin system 193
systemic hormonal preparations, excl. sex hormones and insulins 193
stomatological preparations 192
diuretics 190
antiinfectives for systemic use 184
psychoanaleptics 182
musculo-skeletal system 173
antihistamines for systemic use 172
psycholeptics 172
hmg coa reductase inhibitors 171
antibacterials for systemic use 169
cond_180_days n_180_days
inflammation of specific body systems 282
inflammation of specific body organs 275
pain 273
pain finding at anatomical site 273
arthropathy 263
heart disease 263
vascular disorder 239
diabetes mellitus 235
measurement finding outside reference range 235
soft tissue lesion 227
type 2 diabetes mellitus 225
pain of truncal structure 221
neoplastic disease 208
structural disorder of heart 192
cardiac arrhythmia 188
degenerative disorder of musculoskeletal system 181
abnormal blood cell count 180
osteoarthritis 180
measurement finding below reference range 174
arteriosclerotic vascular disease 172
anemia 170
cytopenia 170
erythropenia 170
hemoglobin level outside reference range 170
hemoglobin low 170